Recruiting Cancer Clinical Trials

CA057-001

A Phase 3, Randomized, Multicenter, Open-Label Study, Comparing CC-92480, Bortezomib and Dexamethasone (480Vd), with Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM)
Description: This trial compares the effectiveness of 2 combination treatments (CC-92480, Bortezomib and Dexamethasone combination v's Pomalidomide, Bortezomib and Dexamethasone combination ) in patients with Relapsed or Refractory Multiple Myeloma
Study Phase: Phase 3
Principal Investigator: Dr Patrick Hayden
Further information

Isa-RVD

Phase II, Multi-centre, Single-Arm, Open-Label Study to evaluate the efficacy and safety of the combination regimen Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma
Description: This is a single arm trial assessing the effectiveness of the combination of Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma
Study Phase: Phase 2
Principal Investigator: Dr Patrick Hayden
Further information

MAJESTEC-4

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Description: This is a multicenter, randomized, open-label, Phase 3 study in participants with newly diagnosed multiple myeloma to evaluate the benefits of teclistamab in combination with lenalidomide and teclistamab alone versus lenalidomide alone as maintenance therapy after autologous stem cell transplant.
Study Phase: Phase 3
Principal Investigator: Dr Patrick Hayden
Further information